Literature DB >> 19118001

Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B.

Elizabeth Hopper-Borge1, Xiu Xu, Tong Shen, Zhi Shi, Zhe-Sheng Chen, Gary D Kruh.   

Abstract

Multidrug resistance protein 7 (MRP7; ABCC10) is an ATP-binding cassette transporter which is able to transport amphipathic anions and confer resistance to docetaxel and, to a lesser extent, vincristine and paclitaxel. Whereas some detail on the resistance profile of MRP7 is known, the activities of the pump have not been completely determined. Here, it is shown by the analysis of MRP7-transfected HEK293 cells that, in addition to natural product agents, MRP7 is also able to confer resistance to nucleoside-based agents, such as the anticancer agents cytarabine (Ara-C) and gemcitabine, and the antiviral agents 2',3'-dideoxycytidine and PMEA. Consistent with the operation of an efflux pump, expression of MRP7 reduced the accumulation of Ara-C and PMEA. In addition, MRP7 is also able to confer resistance to the microtubule-stabilizing agent epothilone B. Ectopic expression of MRP7 in mouse embryo fibroblasts deficient in P-glycoprotein and Mrp1 revealed that MRP7 has a broad resistance profile for natural product agents. In this drug-sensitive cellular background, MRP7 conferred high levels of resistance to docetaxel (46-fold), paclitaxel (116-fold), SN-38 (65-fold), daunorubicin (7.5-fold), etoposide (11-fold), and vincristine (56-fold). Buthionine sulfoximine did not attenuate MRP7-conferred resistance to docetaxel or Ara-C. These experiments indicate that the resistance capabilities of MRP7 include nucleoside-based agents and a range of natural product anticancer agents that includes nontaxane antimicrotubule agents that are not susceptible to P-glycoprotein-mediated transport and that, unlike MRP1 and MRP2, MRP7-mediated drug transport does not involve glutathione.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118001      PMCID: PMC2745904          DOI: 10.1158/0008-5472.CAN-08-1420

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice.

Authors:  Gary D Kruh; Martin G Belinsky; James M Gallo; Kun Lee
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

2.  Analysis of the in vivo functions of Mrp3.

Authors:  Martin G Belinsky; Paul A Dawson; Irina Shchaveleva; Lisa J Bain; Renxue Wang; Victor Ling; Zhe-Sheng Chen; Alex Grinberg; Heiner Westphal; Andres Klein-Szanto; Anthony Lerro; Gary D Kruh
Journal:  Mol Pharmacol       Date:  2005-04-06       Impact factor: 4.436

Review 3.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.

Authors:  Roger G Deeley; Christopher Westlake; Susan P C Cole
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

4.  Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts.

Authors:  Z Ping Lin; Dennis R Johnson; Rick A Finch; Martin G Belinsky; Gary D Kruh; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2002-10       Impact factor: 6.261

5.  The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice.

Authors:  D R Johnson; R A Finch; Z P Lin; C J Zeiss; A C Sartorelli
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

6.  Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells.

Authors:  K Lee; A J Klein-Szanto; G D Kruh
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance.

Authors:  J D Allen; R F Brinkhuis; L van Deemter; J Wijnholds; A H Schinkel
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

9.  Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily.

Authors:  E Hopper; M G Belinsky; H Zeng; A Tosolini; J R Testa; G D Kruh
Journal:  Cancer Lett       Date:  2001-01-26       Impact factor: 8.679

Review 10.  Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

Authors:  T Fojo; M Menefee
Journal:  Ann Oncol       Date:  2007-07       Impact factor: 32.976

View more
  47 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

Review 2.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

3.  Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.

Authors:  Dan Rudin; Liang Li; Nifang Niu; Krishna R Kalari; Judith A Gilbert; Matthew M Ames; Liewei Wang
Journal:  J Drug Metab Toxicol       Date:  2011-02-02

Review 4.  Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.

Authors:  Sau Wai Hung; Hardik R Mody; Rajgopal Govindarajan
Journal:  Cancer Lett       Date:  2012-03-13       Impact factor: 8.679

Review 5.  Taccalonolides: Novel microtubule stabilizers with clinical potential.

Authors:  April L Risinger; Susan L Mooberry
Journal:  Cancer Lett       Date:  2009-10-31       Impact factor: 8.679

6.  Identification of a human ABCC10 orthologue in Catharanthus roseus reveals a U12-type intron determinant for the N-terminal domain feature.

Authors:  Taissir El-Guizani; Clotilde Guibert; Saida Triki; Benoit St-Pierre; Eric Ducos
Journal:  J Genet       Date:  2014-04       Impact factor: 1.166

7.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

8.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

Review 9.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

10.  Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Authors:  Tong Shen; Ye-Hong Kuang; Charles R Ashby; Yu Lei; Angel Chen; Ying Zhou; Xiang Chen; Amit K Tiwari; Elizabeth Hopper-Borge; Jiangyong Ouyang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.